JP2018514523A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514523A5
JP2018514523A5 JP2017553915A JP2017553915A JP2018514523A5 JP 2018514523 A5 JP2018514523 A5 JP 2018514523A5 JP 2017553915 A JP2017553915 A JP 2017553915A JP 2017553915 A JP2017553915 A JP 2017553915A JP 2018514523 A5 JP2018514523 A5 JP 2018514523A5
Authority
JP
Japan
Prior art keywords
tablet
ribocyclic
rib
ribocyclib
succinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/052136 external-priority patent/WO2016166703A1/en
Publication of JP2018514523A publication Critical patent/JP2018514523A/ja
Publication of JP2018514523A5 publication Critical patent/JP2018514523A5/ja
Pending legal-status Critical Current

Links

JP2017553915A 2015-04-16 2016-04-14 リボシクリブ錠剤 Pending JP2018514523A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
US62/148,240 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (2)

Publication Number Publication Date
JP2018514523A JP2018514523A (ja) 2018-06-07
JP2018514523A5 true JP2018514523A5 (enExample) 2019-05-23

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553915A Pending JP2018514523A (ja) 2015-04-16 2016-04-14 リボシクリブ錠剤

Country Status (29)

Country Link
US (6) US10799506B2 (enExample)
EP (3) EP4620458A3 (enExample)
JP (1) JP2018514523A (enExample)
KR (2) KR102750931B1 (enExample)
CN (2) CN115554257A (enExample)
AR (1) AR104257A1 (enExample)
AU (5) AU2016248017A1 (enExample)
BR (1) BR112017021283A2 (enExample)
CA (1) CA2982425C (enExample)
CL (1) CL2017002593A1 (enExample)
CO (1) CO2017010510A2 (enExample)
DK (1) DK3283058T3 (enExample)
EA (1) EA201792290A1 (enExample)
EC (1) ECSP17075052A (enExample)
ES (1) ES2938261T3 (enExample)
FI (1) FI3283058T3 (enExample)
HR (1) HRP20230053T1 (enExample)
HU (1) HUE061213T2 (enExample)
IL (1) IL254818A0 (enExample)
MX (1) MX2017013350A (enExample)
PE (1) PE20180035A1 (enExample)
PH (1) PH12017501820A1 (enExample)
PL (1) PL3283058T3 (enExample)
PT (1) PT3283058T (enExample)
SG (1) SG11201708084PA (enExample)
SI (1) SI3283058T1 (enExample)
TN (1) TN2017000422A1 (enExample)
TW (1) TW201642864A (enExample)
WO (1) WO2016166703A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
EP4021450B1 (en) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL293940A (en) 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cancer drugs cdk4/6 inhibitors
CA3164619A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
KR20230079187A (ko) * 2020-09-29 2023-06-05 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. 고지혈증 및 심혈관 질환의 치료 및 예방을 위한 스타틴 및 피브레이트의 약학적 병용
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
TWI866427B (zh) 2022-08-31 2024-12-11 美商亞文納營運公司 雌激素受體降解劑之給藥方案
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
IN2015DN01046A (enExample) * 2012-07-13 2015-06-26 Gtx Inc
EP3251673A1 (en) * 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
PT2976106T (pt) * 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Similar Documents

Publication Publication Date Title
JP2018514523A5 (enExample)
HRP20230053T1 (hr) Tableta ribocikliba
JP2007302683A5 (enExample)
JP2014218522A5 (enExample)
JP2012255026A5 (enExample)
JP2018184433A5 (enExample)
JP2015078230A5 (enExample)
JP2012530141A5 (enExample)
JP2015205922A5 (enExample)
JP2014167026A5 (enExample)
JP2017048194A5 (enExample)
JP2009545560A5 (enExample)
JP2012107021A5 (enExample)
JP2019513639A5 (enExample)
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
MX2020000332A (es) Preparacion que comprende vonoprazan.
CN109415361A (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
JP2017515879A5 (enExample)
JP2014218523A5 (enExample)
JP2011079754A5 (enExample)
RU2015140119A (ru) Таблетка, покрытая кишечнорастворимым покрытием
CN109803654A (zh) 一种多奈哌齐半帕莫酸盐的粉针剂、包含其的组合物及它们的制备方法
JP2020099679A5 (enExample)
CN106794183A (zh) 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
JP2018039810A5 (enExample)